Profile data is unavailable for this security.
About the company
Oncocyte Corporation is a precision diagnostics company. The Company is engaged in the development of Oncocytes tests and the acquisition of proprietary molecular technologies in the fields of oncology and transplantation. The Company’s products include DetermaIO, VitaGraft, DetermaCNI and GraftAssure. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaIO measures the expression level of 27 selected genes, which are interpreted through the use of a proprietary algorithm (patent pending) which computes a quantitative score (IO Score) that incorporates information from the immune inflammatory infiltrates within and around the tumor. Its pipeline test, DetermaCNI, is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. VitaGraft is a blood-based solid organ transplantation monitoring test. GraftAssure is a research use only blood-based solid organ transplantation monitoring test.
- Revenue in USD (TTM)1.02m
- Net income in USD-36.80m
- Incorporated2009
- Employees43.00
- LocationOncoCyte Corp15 CUSHINGIRVINE 92618United StatesUSA
- Phone+1 (949) 409-7600
- Fax+1 (510) 521-3389
- Websitehttps://oncocyte.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clene Inc. | 442.00k | -30.46m | 43.14m | 82.00 | -- | -- | -- | 97.61 | -4.74 | -4.74 | 0.0688 | -0.0783 | 0.0082 | 1.89 | 5.49 | 5,390.24 | -56.31 | -39.43 | -81.90 | -47.32 | 81.00 | -- | -6,890.50 | -5,261.20 | 0.993 | -16.96 | 1.02 | -- | 38.27 | -- | -65.47 | -- | -- | -- |
| Xilio Therapeutics Inc | 2.36m | -65.53m | 43.52m | 73.00 | -- | 1.30 | -- | 18.46 | -2.11 | -2.11 | 0.067 | 0.7603 | 0.0259 | -- | -- | 32,287.67 | -71.92 | -- | -102.96 | -- | -- | -- | -2,780.27 | -- | -- | -166.76 | 0.00 | -- | -- | -- | 13.40 | -- | -- | -- |
| Hookipa Pharma Inc | 52.16m | -48.60m | 45.33m | 151.00 | -- | 0.5266 | -- | 0.8689 | -5.28 | -5.28 | 4.85 | 7.14 | 0.33 | -- | 309.57 | 345,450.30 | -30.74 | -41.63 | -40.15 | -50.26 | -- | -- | -93.16 | -366.65 | -- | -- | 0.00 | -- | 41.27 | 21.41 | -25.67 | -- | 14.11 | -- |
| Provectus Biopharmaceuticals Inc | 683.90k | -2.79m | 45.35m | 4.00 | -- | -- | -- | 66.31 | -0.0067 | -0.0067 | 0.0016 | -0.0179 | 0.5379 | -- | 613.36 | 170,975.00 | -219.43 | -276.33 | -- | -- | -- | -- | -407.97 | -1,667.76 | -- | -9.75 | -- | -- | -43.61 | -- | 12.74 | -- | -- | -- |
| Intensity Therapeutics Inc | 0.00 | -15.08m | 45.45m | 5.00 | -- | 8.47 | -- | -- | -1.10 | -1.10 | 0.00 | 0.3898 | 0.00 | -- | -- | 0.00 | -112.08 | -- | -146.09 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -56.45 | -- | -- | -- |
| Vyne Therapeutics Inc | 486.00k | -27.86m | 46.61m | 10.00 | -- | 0.6135 | -- | 95.90 | -2.41 | -2.57 | 0.0162 | 5.15 | 0.0087 | -- | -- | 48,600.00 | -49.92 | -108.41 | -59.60 | -138.57 | -- | -- | -5,732.31 | -1,907.10 | -- | -- | 0.00 | -- | -11.11 | -47.51 | 17.89 | -- | -- | -- |
| Calcimedica Inc | 0.00 | -12.59m | 46.74m | 14.00 | -- | 2.70 | -- | -- | -1.88 | -1.88 | 0.00 | 1.29 | 0.00 | -- | -- | 0.00 | -60.97 | -63.99 | -75.48 | -72.71 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 3.51 | -- | -44.35 | -- |
| OncoCyte Corp | 1.02m | -36.80m | 48.15m | 43.00 | -- | 1.68 | -- | 47.07 | -4.26 | -4.26 | 0.1087 | 1.70 | 0.0126 | -- | 1.14 | 23,790.70 | -44.55 | -35.11 | -49.04 | -39.71 | 8.11 | -- | -3,532.75 | -2,373.36 | -- | -154.75 | 0.0212 | -- | 56.89 | -- | -34.84 | -- | 55.41 | -- |
| LAVA Therapeutics NV | 7.40m | -24.18m | 48.63m | 37.00 | -- | 1.13 | -- | 6.57 | -0.8976 | -0.8976 | 0.2741 | 1.63 | 0.0689 | -- | 3.23 | 199,946.00 | -22.51 | -- | -27.11 | -- | 97.78 | -- | -326.89 | -- | -- | -- | 0.1257 | -- | -65.09 | -- | -31.55 | -- | -- | -- |
| BioVie Inc | 0.00 | -33.01m | 48.84m | 14.00 | -- | 1.10 | -- | -- | -7.92 | -7.92 | 0.00 | 2.51 | 0.00 | -- | -- | 0.00 | -106.51 | -330.64 | -176.17 | -875.72 | -- | -- | -- | -- | -- | -- | 0.2688 | -- | -- | -- | 34.32 | -- | -- | -- |
| Kronos Bio Inc | 8.41m | -102.85m | 49.74m | 58.00 | -- | 0.4038 | -- | 5.91 | -1.75 | -1.75 | 0.1425 | 2.04 | 0.0396 | -- | -- | 135,661.30 | -48.41 | -35.47 | -53.26 | -37.14 | -- | -- | -1,222.83 | -7,975.76 | -- | -- | 0.00 | -- | -- | -- | 15.41 | -- | -8.78 | -- |
| Protara Therapeutics Inc | 0.00 | -40.69m | 52.40m | 26.00 | -- | 0.5693 | -- | -- | -3.19 | -3.19 | 0.00 | 4.46 | 0.00 | -- | -- | 0.00 | -41.35 | -37.02 | -43.70 | -38.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 38.71 | -- | -17.67 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Broadwood Capital, Inc.as of 02 Oct 2024 | 6.24m | 46.69% |
| AWM Investment Co., Inc.as of 30 Jun 2024 | 1.10m | 8.20% |
| Pura Vida Investments LLCas of 30 Jun 2024 | 495.35k | 3.70% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 242.17k | 1.81% |
| Geode Capital Management LLCas of 30 Jun 2024 | 92.69k | 0.69% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Jun 2024 | 78.70k | 0.59% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 71.72k | 0.54% |
| Defender Capital LLCas of 30 Sep 2024 | 59.35k | 0.44% |
| FNY Capital Management LPas of 30 Sep 2024 | 42.90k | 0.32% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 19.55k | 0.15% |
